{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T14:41:13Z","timestamp":1786286473372,"version":"build-2736575974"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"32","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with severe infections and a pre-existing indication for antithrombotic therapy, i.e. antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. Bacterial and viral pathogens constitute an increasing threat to global public health, especially for patients with ongoing antithrombotic treatment who have a high risk of thrombotic recurrences and high susceptibility to severe infections with increased morbidity and mortality. Similarly, sepsis survivors are at increased risk for major vascular events. Coagulopathy, which often complicates severe infections, is associated with a high mortality and obligates clinicians to adjust antithrombotic drug type and dosing to avoid bleeding while preventing thrombotic complications. This clinical consensus statement reviews the best available evidence to provide expert opinion and statements on the management of patients hospitalized for severe bacterial or viral infections with a pre-existing indication for antithrombotic therapy (single or combined), in whom sepsis-induced coagulopathy is often observed. Balancing the risk of thrombosis and bleeding in these patients and preventing infections with vaccines, if available, are crucial to prevent events or improve outcomes and prognosis.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehad388","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:26:22Z","timestamp":1685532382000},"page":"3040-3058","source":"Crossref","is-referenced-by-count":25,"title":["Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4508-7990","authenticated-orcid":false,"given":"Bruna","family":"Gigante","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet , Solnav\u00e4gen 30. 17164 and Department of Cardiology, Danderyds Hospital, Entr\u00e9v\u00e4gen 2, 182 88, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H","family":"Levy","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology, Critical Care, and Surgery (Cardiothoracic), Duke University School of Medicine , Durham, United States; 2301 Erwin Road, Durham, NC 27710 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-6678","authenticated-orcid":false,"given":"Eric","family":"van Gorp","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC , Rotterdam, PO box 2040 [Room Ee1726], 3000 CA Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-1523","authenticated-orcid":false,"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Infectious Diseases Unit, University of Florence , Largo Brambilla 3, 50100 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-8932","authenticated-orcid":false,"given":"Marie-Luce","family":"Bochaton-Piallat","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Faculty of Medicine, University of Geneva , 1 rue Michel-Servet 1, CH-1211 Gen\u00e8ve ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-5141","authenticated-orcid":false,"given":"Magnus","family":"B\u00e4ck","sequence":"additional","affiliation":[{"name":"Department of Translational Cardiology, Karolinska Institutet and Karolinska University Hospital , CMM L8:01, 171 76 Stockholm ,","place":["Sweden"]},{"name":"INSERM U1116, University of Lorraine, Nancy University Hospital , 2 rue Jean Lamour, 54505 Vandoeuvre les Nancy Cedex ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-4463","authenticated-orcid":false,"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Thrombosis Expertise Center, Maastricht University Medical Center and CARIM school for cardiovascular diseases , Universiteitsingel 50, PO Box 616, 6200 MD Maastricht ,","place":["The Netherlands"]},{"name":"Center for Thrombosis and Haemostasis, Gutenberg University Medical Center , Langenbeckstr. 1, Bldg. 403, 55131 Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-8084","authenticated-orcid":false,"given":"Christina","family":"Christersson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , Akademiska Sjukhuset, 75185, Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-9575","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Ferreiro","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Bio-Heart Cardiovascular Diseases Research Group; Bellvitge University Hospital \u2013 Bellvitge Biomedical Research Institute (IDIBELL); CIBERCV; L\u2019Hospitalet de Llobregat, Hospital Duran i Reynals - Edifici Terap\u00e8utic - 2a planta Gran Via de l'Hospitalet , 199, 08908 Hospitalet de Llobregat Barcelona \u2013 \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-6038","authenticated-orcid":false,"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Hospital T\u00fcbingen, Otfried-M\u00fcller-Stra\u00dfe 10 , 72076 T\u00fcbingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-5744","authenticated-orcid":false,"given":"Esther","family":"Lutgens","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Experimental CardioVascular Immunology Laboratory, Mayo Clinic , 200 First St SW, 55905, Rochester, MN ,","place":["USA"]},{"name":"Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians Universit\u00e4t, M\u00fcnchen, Germany & German Center for Cardiovascular Research (DZHK) , partner site Munich Heart Alliance, Pettenkoferstrasse 9, 80336, Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[{"name":"Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada HHS - General Hospital 237 , Barton Street East, Hamilton, ON, L8L 2X2 ,","place":["Canada"]},{"name":"Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University , Bol'shaya Pirogovskaya Ulitsa, 2, \u0441\u0442\u0440. 4, Moscow 119435 ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Pegasus House, 463a Glossop Road, Sheffield, S10 2QD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7218-0993","authenticated-orcid":false,"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[{"name":"Department of Haematology, Manchester University Hospitals, Oxford road , Manchester, M13 9WL ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-8873","authenticated-orcid":false,"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[{"name":"Institut de Recerca Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, CIBERCV, Avda. Sant Antoni Maria Claret 167 , 08025 Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-1393","authenticated-orcid":false,"given":"Patricia C","family":"Liaw","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thrombosis & Atherosclerosis Research Institute (TaARI), McMaster University , 237 Barton Street East Hamilton, Ontario L8L 2X2 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Section on Pharmacology, Catholic University School of Medicine , Largo F. Vito 1, 00168 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"2026080909465363500_ehad388-B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-0039-1694995","article-title":"Sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"46","author":"Iba","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2026080909465363500_ehad388-B2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","article-title":"Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms","volume":"133","author":"Jackson","year":"2019","journal-title":"Blood"},{"key":"2026080909465363500_ehad388-B3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13613-017-0339-5","article-title":"Immunohaemostasis: a new view on haemostasis during sepsis","volume":"7","author":"Delabranche","year":"2017","journal-title":"Ann Intensive Care"},{"key":"2026080909465363500_ehad388-B4"},{"key":"2026080909465363500_ehad388-B5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/heartjnl-2016-309402","article-title":"Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies","volume":"102","author":"Adelborg","year":"2016","journal-title":"Heart"},{"key":"2026080909465363500_ehad388-B6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00228-021-03250-6","article-title":"Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study","volume":"78","author":"Garc\u00eda Rodr\u00edguez","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026080909465363500_ehad388-B7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.arcmed.2021.07.003","article-title":"Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment","volume":"52","author":"Iba","year":"2021","journal-title":"Arch Med Res"},{"key":"2026080909465363500_ehad388-B8","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/jth.14578","article-title":"Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"17","author":"Iba","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B9","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2026080909465363500_ehad388-B11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0885066618773679","article-title":"Newly proposed sepsis-induced coagulopathy precedes international society on thrombosis and haemostasis overt-disseminated intravascular coagulation and predicts high mortality","volume":"35","author":"Iba","year":"2020","journal-title":"J Intensive Care Med"},{"key":"2026080909465363500_ehad388-B12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/1076029618770273","article-title":"Sepsis-induced coagulopathy and Japanese association for acute medicine DIC in coagulopathic patients with decreased antithrombin and treated by antithrombin","volume":"24","author":"Iba","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026080909465363500_ehad388-B13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-0038-1676610","article-title":"External validation of the two newly proposed criteria for assessing coagulopathy in sepsis","volume":"119","author":"Yamakawa","year":"2019","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MBC.0000000000000755","article-title":"Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: a retrospective study","volume":"29","author":"Ding","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026080909465363500_ehad388-B15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2026080909465363500_ehad388-B16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/CCM.0000000000002997","article-title":"Sepsis-associated coagulopathy severity predicts hospital mortality","volume":"46","author":"Lyons","year":"2018","journal-title":"Crit Care Med"},{"key":"2026080909465363500_ehad388-B17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0169-2070(99)00018-7","article-title":"The Delphi technique as a forecasting tool: issues and analysis","volume":"15","author":"Rowe G","year":"1999","journal-title":"Int J Forecasting"},{"key":"2026080909465363500_ehad388-B18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/eurheartj\/ehab697","article-title":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2\u2014care pathways, treatment, and follow-up","volume":"43","author":"Task Force for the management of COVID-19 of the European Society of Cardiology.","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B19","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"Schulman","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/09537104.2020.1817360","article-title":"Immunothrombosis and thromboinflammation in host defense and disease","volume":"32","author":"Martinod K","year":"2021","journal-title":"Platelets"},{"key":"2026080909465363500_ehad388-B21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1160\/TH03-11-0701","article-title":"Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1","volume":"91","author":"Tanguay","year":"2004","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B22","first-page":"112","article-title":"The pulmonary vascular lesions of the adult respiratory distress syndrome","volume":"112","author":"Tomashefski","year":"1983","journal-title":"Am J Pathol"},{"key":"2026080909465363500_ehad388-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ijlh.13500","article-title":"COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations","volume":"43","author":"Levy","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2026080909465363500_ehad388-B24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026080909465363500_ehad388-B25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2026080909465363500_ehad388-B26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/ATVBAHA.121.316930","article-title":"Staphylococcus aureus and neutrophil extracellular traps: the master manipulator meets its match in immunothrombosis","volume":"42","author":"Meyers","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080909465363500_ehad388-B27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/jth.13911","article-title":"Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis","volume":"16","author":"Iba","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B28","article-title":"NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"2026080909465363500_ehad388-B29","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1055\/s-0038-1649961","article-title":"Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock","volume":"74","author":"Wuillemin","year":"1995","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B30","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V87.6.2337.bloodjournal8762337","article-title":"Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase","volume":"87","author":"Jansen","year":"1996","journal-title":"Blood"},{"key":"2026080909465363500_ehad388-B31","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058205","article-title":"Trends in bacterial sepsis incidence and mortality in France between 2015 and 2019 based on National Health Data System (Systeme National des donnees de Sante (SNDS)): a retrospective observational study","volume":"12","author":"Pandolfi","year":"2022","journal-title":"BMJ Open"},{"key":"2026080909465363500_ehad388-B33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change","volume":"20","author":"Baker","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2026080909465363500_ehad388-B34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4161\/viru.27372","article-title":"Epidemiology of severe sepsis","volume":"5","author":"Mayr","year":"2014","journal-title":"Virulence"},{"key":"2026080909465363500_ehad388-B35","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"2026080909465363500_ehad388-B36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/rth2.12406","article-title":"Antiviral anticoagulation","volume":"4","author":"Pryzdial","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2026080909465363500_ehad388-B37","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3389\/fimmu.2020.01962","article-title":"Crosstalk between platelets and microbial pathogens","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2026080909465363500_ehad388-B38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026080909465363500_ehad388-B39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4161\/viru.27024","article-title":"Gram-positive and gram-negative bacterial toxins in sepsis: a brief review","volume":"5","author":"Ramachandran","year":"2014","journal-title":"Virulence"},{"key":"2026080909465363500_ehad388-B40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/jcm8050728","article-title":"Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation","volume":"8","author":"Iba","year":"2019","journal-title":"J Clin Med"},{"key":"2026080909465363500_ehad388-B41","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3389\/fimmu.2018.02147","article-title":"Epidemiology and immune pathogenesis of viral sepsis","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"2026080909465363500_ehad388-B42","author":"Anesi"},{"key":"2026080909465363500_ehad388-B43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026080909465363500_ehad388-B44","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2214-109X(17)30007-4","article-title":"Causes and outcomes of sepsis in Southeast Asia: a multinational multicentre cross-sectional study","volume":"5","author":"Southeast Asia Infectious Disease Clinical Research Network","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026080909465363500_ehad388-B45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B46","volume-title":"Integrating Neglected Tropical Diseases Into Global Health and Development: Fourth WHO Report on Neglected Tropical Diseases","author":"World Health Organization"},{"key":"2026080909465363500_ehad388-B47","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/jmv.23354","article-title":"Review: viral infections and mechanisms of thrombosis and bleeding","volume":"84","author":"Goeijenbier","year":"2012","journal-title":"J Med Virol"},{"key":"2026080909465363500_ehad388-B48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/jcm10040877","article-title":"Thrombocytopenia in virus infections","volume":"10","author":"Raadsen","year":"2021","journal-title":"J Clin Med"},{"key":"2026080909465363500_ehad388-B49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2180-14-134","article-title":"Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets","volume":"14","author":"Goeijenbier","year":"2014","journal-title":"BMC Microbiol"},{"key":"2026080909465363500_ehad388-B50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B52","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019589","article-title":"Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC\/AHA multisociety cholesterol treatment guidelines over the pooled cohort equation: insights from 3 large prospective cohorts","volume":"10","author":"Akintoye","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080909465363500_ehad388-B53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2022.06.018","article-title":"Major global coronary artery calcium guidelines","volume":"16","author":"Golub I","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465363500_ehad388-B54","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2020.07.027","article-title":"A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications","volume":"309","author":"Oikonomou","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026080909465363500_ehad388-B55","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc10-1185","article-title":"Diabetes and sepsis: preclinical findings and clinical relevance","volume":"34","author":"Schuetz","year":"2011","journal-title":"Diabetes Care"},{"key":"2026080909465363500_ehad388-B56","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.26.2.510","article-title":"Quantifying the risk of infectious diseases for people with diabetes","volume":"26","author":"Shah","year":"2003","journal-title":"Diabetes Care"},{"key":"2026080909465363500_ehad388-B57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2026080909465363500_ehad388-B58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12871-017-0405-4","article-title":"The role of increased body mass index in outcomes of sepsis: a systematic review and meta-analysis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Anesthesiol"},{"key":"2026080909465363500_ehad388-B59","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/oby.23245","article-title":"Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVID-19 in the US","volume":"29","author":"Friedman","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2026080909465363500_ehad388-B60","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41366-021-00776-8","article-title":"Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis","volume":"45","author":"Aghili","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2026080909465363500_ehad388-B61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/CIRCULATIONAHA.120.051936","article-title":"Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry","volume":"143","author":"Hendren","year":"2021","journal-title":"Circulation"},{"key":"2026080909465363500_ehad388-B62","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1378\/chest.120.6.1989","article-title":"Morbid obesity in the medical ICU","volume":"120","author":"El-Solh","year":"2001","journal-title":"Chest"},{"key":"2026080909465363500_ehad388-B63","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1097\/CCM.0000000000004459","article-title":"Sepsis and the obesity paradox: size matters in more than one way","volume":"48","author":"Jagan","year":"2020","journal-title":"Crit Care Med"},{"key":"2026080909465363500_ehad388-B64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13054-016-1360-z","article-title":"Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis","volume":"20","author":"Pepper","year":"2016","journal-title":"Crit Care"},{"key":"2026080909465363500_ehad388-B65","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes","volume":"109","author":"Sarkiss","year":"2007","journal-title":"Cancer"},{"key":"2026080909465363500_ehad388-B66","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"Hemasphere"},{"key":"2026080909465363500_ehad388-B67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.phrs.2009.01.011","article-title":"Nonsteroidal antiinflammatory drugs: past, present and future","volume":"59","author":"Patrono","year":"2009","journal-title":"Pharmacol Res"},{"key":"2026080909465363500_ehad388-B68","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.0405445101","article-title":"Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial","volume":"101","author":"Chiang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026080909465363500_ehad388-B69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","journal-title":"Lancet"},{"key":"2026080909465363500_ehad388-B70","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"2026080909465363500_ehad388-B71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11239-022-02746-x","article-title":"Comprehensive collection of COVID-19 related prosthetic valve failure: a systematic review","volume":"55","author":"Trieu","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"2026080909465363500_ehad388-B72","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.989903","article-title":"Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: a meta-analysis","volume":"13","author":"Su","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026080909465363500_ehad388-B73","doi-asserted-by":"crossref","first-page":"n311","DOI":"10.1136\/bmj.n311","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"2026080909465363500_ehad388-B74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.21873\/invivo.12305","article-title":"Beneficial effects of intermediate dosage of anticoagulation treatment on the prognosis of hospitalized COVID-19 patients: the ETHRA study","volume":"35","author":"Poulakou","year":"2021","journal-title":"In Vivo"},{"key":"2026080909465363500_ehad388-B75","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2020.08.041","article-title":"Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19","volume":"76","author":"Nadkarni","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B76","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B77","first-page":"233","article-title":"COVID-19, the pandemic of the century and its impact on cardiovascular diseases","volume":"1","author":"Zhang","year":"2021","journal-title":"Cardiol Discov"},{"key":"2026080909465363500_ehad388-B78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.thromres.2018.04.007","article-title":"Platelet activation and antiplatelet therapy in sepsis: a narrative review","volume":"166","author":"Wang","year":"2018","journal-title":"Thromb Res"},{"key":"2026080909465363500_ehad388-B79","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/CIRCULATIONAHA.106.678359","article-title":"Sepsis and the heart","volume":"116","author":"Merx","year":"2007","journal-title":"Circulation"},{"key":"2026080909465363500_ehad388-B80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.201510-2023OC","article-title":"Long-term mortality and major adverse cardiovascular events in sepsis survivors. A nationwide population-based study","volume":"194","author":"Ou","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080909465363500_ehad388-B81","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1378\/chest.10-0891","article-title":"Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study","volume":"139","author":"Erlich","year":"2011","journal-title":"Chest"},{"key":"2026080909465363500_ehad388-B82","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/720254","article-title":"Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?","volume":"2012","author":"Losche","year":"2012","journal-title":"Thrombosis"},{"key":"2026080909465363500_ehad388-B83","article-title":"Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study","volume":"2013","author":"Valerio-Rojas","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"2026080909465363500_ehad388-B84","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00134-015-3760-y","article-title":"Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study","volume":"41","author":"Tsai","year":"2015","journal-title":"Intensive Care Med"},{"key":"2026080909465363500_ehad388-B85","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/CCM.0000000000002654","article-title":"Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: an individual patient data meta-analysis using propensity matching","volume":"45","author":"Trauer","year":"2017","journal-title":"Crit Care Med"},{"key":"2026080909465363500_ehad388-B86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcrc.2018.12.004","article-title":"Effects of antiplatelet therapy on the mortality rate of patients with sepsis: a meta-analysis","volume":"50","author":"Ouyang","year":"2019","journal-title":"J Crit Care"},{"key":"2026080909465363500_ehad388-B87","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/jth.15517","article-title":"Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: a propensity score-matched analysis","volume":"19","author":"Chow","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00134-015-4171-9","article-title":"Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: a propensity-matched analysis","volume":"42","author":"Wiewel","year":"2016","journal-title":"Intensive Care Med"},{"key":"2026080909465363500_ehad388-B89","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B90","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists C","year":"2009","journal-title":"Lancet"},{"key":"2026080909465363500_ehad388-B91","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ahj.2010.11.001","article-title":"Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial","volume":"161","author":"Hakim","year":"2011","journal-title":"Am Heart J"},{"key":"2026080909465363500_ehad388-B92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1634\/theoncologist.2016-0110","article-title":"Aspirin is associated with improved survival in severely thrombocytopenic cancer patients with acute myocardial infarction","volume":"22","author":"Feher","year":"2017","journal-title":"Oncologist"},{"key":"2026080909465363500_ehad388-B93","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"2026080909465363500_ehad388-B94","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026080909465363500_ehad388-B95","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/jcph.2020","article-title":"Heterogeneity in the identification of potential drug-drug interactions in the intensive care unit: a systematic review, critical appraisal, and reporting recommendations","volume":"62","author":"Bakker","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026080909465363500_ehad388-B96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-29423-5_6","article-title":"Aspirin and other COX-1 inhibitors","volume":"210","author":"Patrono","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"2026080909465363500_ehad388-B97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mi.10.1.4","article-title":"Personalized medicine, pharmacogenetics, and clopidogrel: unraveling variability of response","volume":"10","author":"Rocca","year":"2010","journal-title":"Mol Interv"},{"key":"2026080909465363500_ehad388-B98","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cpt.1398","article-title":"Clopidogrel as a perpetrator of drug-drug interactions: a challenge for quantitative predictions?","volume":"105","author":"Varma","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026080909465363500_ehad388-B99","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","article-title":"Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study","volume":"333","author":"Hallas","year":"2006","journal-title":"BMJ"},{"key":"2026080909465363500_ehad388-B100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B101","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"2026080909465363500_ehad388-B102","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14740338.2015.986456","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events","volume":"14","author":"MacLaren","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"2026080909465363500_ehad388-B103","doi-asserted-by":"crossref","first-page":"l6722","DOI":"10.1136\/bmj.l6722","article-title":"Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline","volume":"368","author":"Ye","year":"2020","journal-title":"BMJ"},{"key":"2026080909465363500_ehad388-B104","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","article-title":"A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers","volume":"59","author":"Frelinger","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/CIRCINTERVENTIONS.110.960997","article-title":"Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study","volume":"4","author":"Ferreiro","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080909465363500_ehad388-B106","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.110.957829","article-title":"Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study","volume":"3","author":"Ferreiro","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080909465363500_ehad388-B107"},{"key":"2026080909465363500_ehad388-B108"},{"key":"2026080909465363500_ehad388-B109","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SHK.0000000000001057","article-title":"Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis","volume":"49","author":"Du","year":"2018","journal-title":"Shock"},{"key":"2026080909465363500_ehad388-B110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/heartjnl-2021-319552","article-title":"Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry","volume":"108","author":"Santoro","year":"2022","journal-title":"Heart"},{"key":"2026080909465363500_ehad388-B111","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/archinternmed.2009.42","article-title":"Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery","volume":"169","author":"Blasco-Colmenares","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026080909465363500_ehad388-B112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2020.06.016","article-title":"Effect of ticagrelor on reducing the risk of gram-positive infections in patients with acute coronary syndrome","volume":"130","author":"Lupu","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026080909465363500_ehad388-B113","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","article-title":"Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study","volume":"25","author":"Storey","year":"2014","journal-title":"Platelets"},{"key":"2026080909465363500_ehad388-B114","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1136\/heartjnl-2014-305619","article-title":"Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes","volume":"100","author":"Varenhorst","year":"2014","journal-title":"Heart"},{"key":"2026080909465363500_ehad388-B115","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jacc.2012.07.021","article-title":"Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery","volume":"60","author":"Varenhorst","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/09537104.2021.1934667","article-title":"Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy","volume":"33","author":"Nelson","year":"2022","journal-title":"Platelets"},{"key":"2026080909465363500_ehad388-B117","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"2026080909465363500_ehad388-B118","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1160\/TH16-10-0799","article-title":"A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia","volume":"117","author":"Kiers","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B119","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1055\/s-0041-1733857","article-title":"Platelet P2Y 12 receptor deletion or pharmacological inhibition does not protect mice from sepsis or septic shock","volume":"5","author":"Rabouel","year":"2021","journal-title":"TH Open"},{"key":"2026080909465363500_ehad388-B120","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026080909465363500_ehad388-B121","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1160\/TH11-12-0867","article-title":"Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse","volume":"107","author":"Totani","year":"2012","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B122","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"2026080909465363500_ehad388-B123","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jcin.2017.06.001","article-title":"Risk of early adverse events after clopidogrel discontinuation in patients undergoing short-term dual antiplatelet therapy: an individual participant data analysis","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909465363500_ehad388-B124","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"2026080909465363500_ehad388-B125","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1056\/NEJMoa041747","article-title":"Risk of myocardial infarction and stroke after acute infection or vaccination","volume":"351","author":"Smeeth","year":"2004","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B126","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41569-022-00725-6","article-title":"P2y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026080909465363500_ehad388-B127","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-020-00864-4","article-title":"Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists","volume":"59","author":"Schilling","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026080909465363500_ehad388-B129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B130","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465363500_ehad388-B131","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1055\/s-0038-1657768","article-title":"Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI Study)","volume":"118","author":"Sumaya","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026080909465363500_ehad388-B132","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/09537104.2019.1624707","article-title":"Thrombin-induced platelet aggregation\u2014effect of dabigatran using automated platelet aggregometry\u2212","volume":"31","author":"Shimizu","year":"2020","journal-title":"Platelets"},{"key":"2026080909465363500_ehad388-B133","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1503\/cmaj.070221","article-title":"Pneumococcal vaccination and risk of myocardial infarction","volume":"179","author":"Lamontagne","year":"2008","journal-title":"Cmaj"},{"key":"2026080909465363500_ehad388-B134","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/CCM.0b013e318246b9df","article-title":"Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis","volume":"40","author":"Eisen","year":"2012","journal-title":"Crit Care Med"},{"key":"2026080909465363500_ehad388-B135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.26102","article-title":"Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis","volume":"96","author":"Meizlish","year":"2021","journal-title":"Am J Hematol"},{"key":"2026080909465363500_ehad388-B136","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/09537104.2012.724482","article-title":"Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock","volume":"24","author":"Otto","year":"2013","journal-title":"Platelets"},{"key":"2026080909465363500_ehad388-B137","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jth.13230","article-title":"Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials","volume":"14","author":"Umemura","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026080909465363500_ehad388-B138","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"2026080909465363500_ehad388-B139","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.21037\/apm-21-169","article-title":"Therapeutic effect of low-molecular-weight heparin on adult sepsis: a meta-analysis","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026080909465363500_ehad388-B140","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007453","article-title":"Bleeding complications in anticoagulated patients with atrial fibrillation and sepsis: a propensity-weighted cohort study","volume":"6","author":"S\u00f8gaard","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026080909465363500_ehad388-B141","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/1060028013500938","article-title":"Challenges of anticoagulation for atrial fibrillation in patients with severe sepsis","volume":"47","author":"Darwish","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026080909465363500_ehad388-B142"},{"key":"2026080909465363500_ehad388-B143"},{"key":"2026080909465363500_ehad388-B144"},{"key":"2026080909465363500_ehad388-B145"},{"key":"2026080909465363500_ehad388-B146","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1053\/j.gastro.2016.08.054","article-title":"Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding","volume":"151","author":"Ray","year":"2016","journal-title":"Gastroenterology"},{"key":"2026080909465363500_ehad388-B147","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/heartjnl-2021-319332","article-title":"Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds","volume":"108","author":"Komen","year":"2022","journal-title":"Heart"},{"key":"2026080909465363500_ehad388-B148","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026080909465363500_ehad388-B149","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1503\/cmaj.151059","article-title":"Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes","volume":"188","author":"Vamos","year":"2016","journal-title":"CMAJ"},{"key":"2026080909465363500_ehad388-B150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2020.23649","article-title":"Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial","volume":"325","author":"Vardeny","year":"2021","journal-title":"JAMA"},{"key":"2026080909465363500_ehad388-B151","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2337\/dc20-0229","article-title":"Influenza vaccination is associated with reduced cardiovascular mortality in adults with diabetes: a nationwide cohort study","volume":"43","author":"Modin","year":"2020","journal-title":"Diabetes Care"},{"key":"2026080909465363500_ehad388-B152","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021715","article-title":"Flu vaccine and mortality in hypertension: a nationwide cohort study","volume":"11","author":"Modin","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026080909465363500_ehad388-B153","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2021.03.007","article-title":"Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial","volume":"237","author":"Hollingsworth","year":"2021","journal-title":"Am Heart J"},{"key":"2026080909465363500_ehad388-B154","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/01.CIR.0000016182.85461.F4","article-title":"Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) study","volume":"105","author":"Gurfinkel","year":"2002","journal-title":"Circulation"},{"key":"2026080909465363500_ehad388-B155","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.121.057042","article-title":"Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"144","author":"Frobert","year":"2021","journal-title":"Circulation"},{"key":"2026080909465363500_ehad388-B156","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1093\/eurheartj\/ehac472","article-title":"Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial","volume":"43","author":"Fonseca","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B157","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/eurheartj\/ehr004","article-title":"Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome","volume":"32","author":"Phrommintikul","year":"2011","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B158","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ehj.2003.10.018","article-title":"Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study","volume":"25","author":"Gurfinkel","year":"2004","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B159","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/eurheartj\/ehm581","article-title":"Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study","volume":"29","author":"Ciszewski","year":"2008","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B160","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/eurjpc\/zwac152","article-title":"Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis","volume":"29","author":"Jaiswal","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465363500_ehad388-B161","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1086\/656587","article-title":"Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study","volume":"51","author":"Hung","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026080909465363500_ehad388-B162","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.vaccine.2013.11.017","article-title":"Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: the CAPAMIS study, three-year follow-up","volume":"32","author":"Ochoa-Gondar","year":"2014","journal-title":"Vaccine"},{"key":"2026080909465363500_ehad388-B163","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.047","article-title":"Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS study, 3-year follow-up","volume":"23","author":"Vila-Corcoles","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026080909465363500_ehad388-B164","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000247","article-title":"Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis","volume":"2","author":"Ren","year":"2015","journal-title":"Open Heart"},{"key":"2026080909465363500_ehad388-B165","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeab014","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions","volume":"1","author":"Marchandot","year":"2021","journal-title":"Eur Heart J Open"},{"key":"2026080909465363500_ehad388-B166","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B167","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080909465363500_ehad388-B168","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1093\/eurheartj\/ehab592","article-title":"Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score","volume":"42","author":"Hwang","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465363500_ehad388-B169","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"2026080909465363500_ehad388-B170","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106176","article-title":"COVID-19 and in situ pulmonary artery thrombosis","volume":"176","author":"Mandal","year":"2021","journal-title":"Respir Med"},{"key":"2026080909465363500_ehad388-B171","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.2013.279206","article-title":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis","volume":"310","author":"Udell","year":"2013","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/32\/3040\/60913424\/ehad388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/32\/3040\/60913424\/ehad388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:47:17Z","timestamp":1786283237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/32\/3040\/7223688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":171,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2023,7,13]]},"published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad388","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,21]]},"published":{"date-parts":[[2023,7,13]]}}}